Drug intelligence / Profile preview

PL-AC-343

Development stage: Preclinical
Lead developer: Jiangsu ProteLight Pharmaceutical & Biotechnology
Modality: Small Molecules

Overview

PL-AC-343 is a small molecule drug candidate currently in preclinical development by Jiangsu ProteLight Pharmaceutical & Biotechnology for the treatment of solid tumors. As of early 2024, the specific biological target and mechanism of action for PL-AC-343 remain undisclosed by the developer. The compound is part of the company's broader pipeline, which includes both antimicrobial peptides and targeted oncology therapies. The asset is being investigated for its potential antineoplastic activity against various solid tumor types.

Targets

BDKRB1 (Bradykinin Receptor B1)

Beyond the preview

Go deeper on PL-AC-343.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PL-AC-343.

Explore the full profile